Vaccinex logo
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
15 mai 2024 18h00 HE | Vaccinex, Inc.
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.
logo-horizontal-main.png
Oncocyte Reports First Quarter 2024 Financial Results
15 mai 2024 16h05 HE | OncoCyte Corporation
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sharecare
15 mai 2024 15h45 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sharecare, Inc. (“Sharecare” or the “Company”)...
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
15 mai 2024 15h30 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. (“Akero” or the...
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sonder
15 mai 2024 15h30 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sonder Holdings Inc. (“Sonder” or the...
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho
15 mai 2024 15h15 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against QuidelOrtho Corporation (“QuidelOrtho” or the...
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rivian
15 mai 2024 15h05 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rivian Automotive, Inc. (“Rivian” or the...
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SSR Mining
15 mai 2024 14h55 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SSR Mining Inc. (“SSR Mining” or the “Company”)...
James (Josh) Wilson Faruqi & Faruqi, LLP
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Shoals
15 mai 2024 14h25 HE | Faruqi & Faruqi LLP
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Shoals Technologies Group, Inc. (“Shoals” or...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
15 mai 2024 13h45 HE | Sixty Degrees Pharmaceuticals
SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.